Clarithromycin, rifabutin and clofazimine for treatment of disseminated Mycobacterium avium. Complex disease in AIDS patients

Clinical Drug Investigation

Volumn 17, Issue 3, 1999, Pages 171-178

  Haefner, Mark ^a   Funke Kissling, Pascale ^b   Pfyffer, Gaby E ^b   Lüthy, Ruedi ^a   Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CLARITHROMYCIN; CLOFAZIMINE; RIFABUTIN;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANOREXIA; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG RESISTANCE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PRIORITY JOURNAL; SWEATING; SYMPTOM; UVEITIS; WEIGHT REDUCTION;

EID: 0033006497     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917030-00001     Document Type: Article

References (39)

1. Opravil M, Pechère M, Lazzarin A, et al. Dapsone/pyrimethamine may prevent mycobacterial disease in immunosuppressed patients infected with the human immunodeficiency virus. Clin Infect Dis 1995; 20: 244-9
2. Low N, Pfluger D, Egger M, et al. Disseminated Mycobacterium avium complex disease in the Swiss HIV Cohort Study: increasing incidence, unchanged prognosis. AIDS 1997; 11: 1165-71
3. Chaisson RE, Moore RD, Richman DD, et al. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. Am Rev Respir Dis 1992; 146: 285-9.
4. Jacobson MA, Hopewell PC, Yajko DM, et al. Natural History of disseminated Mycobacterium avium complex infection in AIDS. J Infect Dis 1991; 164: 994-8.
5. Wallace JM, Hannah JB. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome. A clinicopatologic study. Chest 1998; 93: 926-32.
6. Horsburgh Jr CR, Havlik JA, Ellis DA, et al. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy. Am Rev Respir Dis 1991; 144: 557-9.
7. Horburgh Jr CR, Metchock B, Gordon SM, et al. Predictors of survival in patients with AIDS and disseminated Mycobacterium avium complex disease. J Infect Dis 1994; 170: 573-7.
8. Chin DP, Reingold AL, Stone EN, et al. The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients - a prospective study. J Infect Dis 1994; 170: 578-84.
9. Shafran SD, Singer J, Zarowny DP, et al. A comparisun of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS-rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-83.
10. Dautzenberg B, Saint Marc T, Meyobas MC, et al. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1993; 153: 368-72.
11. Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. Ann Intern Med 1994; 121: 905-11.
12. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993; 329: 828-33.
13. Piersimoni C, Tortoli E, Mascellino MT, et al. Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. J Antimicrob Chemother 1995; 36: 497-502.
14. Sullam PM, Gordin FM, Wynne BA, et al. Efficacy rifabutin in the treatment of disseminated infection due to Mycobacterium avium complex. Clin Infect Dis 1994; 19: 84-6.
15. Dautzenberg B, Castellani P, Pellegrin JL, et al. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother 1996; 40: 1722-5.
16. Ghebremichael S, Svenson SB, Kallenius G, et al. Anti-mycobacterial synergism of clarithromycin and rifabutin. Scand J Infect Dis 1997; 28: 387-90.
17. Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen: rifampin, ethambutol, clofazimine, and ciprofloxacin. Ann Intern Med 1992; 116: 466-72.
18. Hoy J, Mijch A, Sandland M, et al. Quadrople-drug therapy for Mycobacterium avium-intracellulare bacteremia in AIDS patients. J Infect Dis 1990; 161: 801-5.
19. Lindholm-Levy PJ, Heifels LB. Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex. Tubercle 1988; 69: 179-86.
20. Kemper CA, Havlir D, Haghighat D, et al. The individual microbiologic effect of three antimycobacterial agents, clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex bacteremia in patients with AIDS. J Infect Dis 1994; 170: 157-64.
21. Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS 1997; 11: 311-7.
22. Hacek D. Modified proportion agar dilution test for slowly growing mycobacteria. In: Isenberg HD, editor. Clinical microbiology procedures handbook. Washington, DC: Amercan Society for Microbiology, 1992: 5.13.1-5.13.15.
23. Heifets L, Lindholm-Levy P, Libonati J, et al. Radiometric broth macrodilution method for determination of minimal inhibitory concentration. (MIC) with Mycobacterium avium complex isolates. Proposed Guidelines. Denver: National Jewish Center for Immunology and Respiratory Medicine; 1993.
24. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 40: 1759-67
25. May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodifeciency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. Clin Infect Dis 1997; 25: 621-9.
26. Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. J Infect Dis 1997; 176: 1225-32.
27. Ward TT, Rimland D, Kauffman C, et al. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Clin Infect Dis 1998; 27: 1278-85.
28. Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. Am Intern Med 1990; 113: 358-61.
29. Jacobson MA, Yajko D, Northfelt D, et al. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis 1993; 168: 112-9.
30. Benson C, Williams P, Currier J, et al. ACTG 223: an open, prospective, randomized study comparing efficacy and safety of clarithromycin plus ethambutol, rifabutin or both for treatment of MAC disease in patients with AIDS [abstract 249]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4: Chicago
31. Horsburgh Jr CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 1332-8
32. Horsburgh Jr CR. Advances in the prevention and treatment of Mycobacterium avium disease. N Engl J Med 1996; 335: 428-30
33. Yajko DM, Sanders CA, Madej JJ, et al. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob Agents Chemother 1996; 40: 743-9.
34. Dautzenberg B, Truffot C, Legris S, et al. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis 1991; 144: 564-9.
35. Burman W, Reves R, Rietmeijer C, et al. Relapse of disseminated Mycobacterium avium complex disease and emergence of resistance to clarithromycin despite treatment with a multidrug regimen [abstract 176.]. In: Program and abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1, Washington DC
36. Nightingale SD, Byrd LT, Southern PM, et al. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-5.
37. Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995; 29: 1149-55.
38. Blaschke TF, Skinner MH. The clinical pharmacokinetics of rifabutin. Clin Infect Dis 1996; 22 Suppl. 1: S15-21.
39. Wallace Jr RJ, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995; 171: 745-50.